Annual Cash & Cash Equivalents
$9.29 M
+$2.86 M+44.55%
31 December 2023
Summary:
Hoth Therapeutics annual cash & cash equivalents is currently $9.29 million, with the most recent change of +$2.86 million (+44.55%) on 31 December 2023. During the last 3 years, it has risen by +$6.66 million (+253.36%). HOTH annual cash & cash equivalents is now at all-time high.HOTH Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$8.02 M
-$1.63 M-16.90%
30 September 2024
Summary:
Hoth Therapeutics quarterly cash and cash equivalents is currently $8.02 million, with the most recent change of -$1.63 million (-16.90%) on 30 September 2024. Over the past year, it has dropped by -$3.81 million (-32.17%). HOTH quarterly cash and cash equivalents is now -58.44% below its all-time high of $19.30 million, reached on 31 March 2021.HOTH Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HOTH Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +44.5% | -32.2% |
| 3 y3 years | +253.4% | -35.5% |
| 5 y5 years | +3188.2% | +149.6% |
HOTH Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +253.4% | -38.5% | +25.7% |
| 5 y | 5 years | at high | +3188.2% | -58.4% | +374.5% |
| alltime | all time | at high | +3188.2% | -58.4% | +2738.9% |
Hoth Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $8.02 M(-16.9%) |
| June 2024 | - | $9.65 M(+27.7%) |
| Mar 2024 | - | $7.56 M(-18.6%) |
| Dec 2023 | $9.29 M(+44.5%) | $9.29 M(-21.4%) |
| Sept 2023 | - | $11.83 M(+2.5%) |
| June 2023 | - | $11.54 M(-11.5%) |
| Mar 2023 | - | $13.04 M(+102.9%) |
| Dec 2022 | $6.43 M(-24.7%) | $6.43 M(-28.1%) |
| Sept 2022 | - | $8.94 M(-21.1%) |
| June 2022 | - | $11.32 M(+77.4%) |
| Mar 2022 | - | $6.38 M(-25.3%) |
| Dec 2021 | $8.54 M | $8.54 M(-31.4%) |
| Sept 2021 | - | $12.45 M(-21.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2021 | - | $15.85 M(-17.9%) |
| Mar 2021 | - | $19.30 M(+634.0%) |
| Dec 2020 | $2.63 M(+55.5%) | $2.63 M(-36.2%) |
| Sept 2020 | - | $4.12 M(-16.7%) |
| June 2020 | - | $4.95 M(+13.7%) |
| Mar 2020 | - | $4.35 M(+157.2%) |
| Dec 2019 | $1.69 M(+498.3%) | $1.69 M(-47.4%) |
| Sept 2019 | - | $3.21 M(-21.4%) |
| June 2019 | - | $4.09 M(-20.8%) |
| Mar 2019 | - | $5.17 M(+1728.1%) |
| Dec 2018 | $282.60 K(-77.0%) | $282.60 K(-61.7%) |
| Sept 2018 | - | $737.70 K |
| Dec 2017 | $1.23 M | - |
FAQ
- What is Hoth Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Hoth Therapeutics?
- What is Hoth Therapeutics annual cash & cash equivalents year-on-year change?
- What is Hoth Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Hoth Therapeutics?
- What is Hoth Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Hoth Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of HOTH is $9.29 M
What is the all time high annual cash & cash equivalents for Hoth Therapeutics?
Hoth Therapeutics all-time high annual cash & cash equivalents is $9.29 M
What is Hoth Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, HOTH annual cash & cash equivalents has changed by +$2.86 M (+44.55%)
What is Hoth Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of HOTH is $8.02 M
What is the all time high quarterly cash and cash equivalents for Hoth Therapeutics?
Hoth Therapeutics all-time high quarterly cash and cash equivalents is $19.30 M
What is Hoth Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, HOTH quarterly cash and cash equivalents has changed by -$3.81 M (-32.17%)